Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.

ABSTRACT:

Objective

To assess the feasibility of clinical pharmacist-led CYP2C19 genotype-guided P2Y₁₂ inhibitor antiplatelet drug therapy recommendations to cardiologists in an outpatient cardiology practice.

Methods

This was a prospective, open-labeled, single-arm study conducted in an integrated healthcare delivery system between March 1, 2013 and January 23, 2014. Patients requiring non-emergent cardiac catheterization were included. A clinical pharmacist provided interpretation and recommendations from genotyping results. The feasibility of implementing CYP2C19 genotype-guided antiplatelet therapy was assessed by the: 1) percentage of patients approached who consented to CYP2C19 genotyping, 2) percentage of patients with CYP2C19 genotyping results available prior to ca

SUBMITTER: Johnson SG 

PROVIDER: S-EPMC5499354 | biostudies-literature | 2017 Apr-Jun

REPOSITORIES: biostudies-literature